Celularity is a clinical stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies, including genetically-modified and unmodified NK cells, engineered T cells, including CAR-T cells, and mesenchymal-like adherent stromal cells (ASCs), targeting indications across cancer, immunologic, infectious, and degenerative diseases. Our goal is to turn living cells into medicines. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta cells. We have various cell therapy candidates in pre-clinical & clinical development and placental-derived products for surgical use. These include Biovance® - a human amniotic membrane allograft that provides a protective cover to support the body’s wound healing processes, & Interfyl® - a Connective Tissue Matrix (CTM) suited for a variety of surgical applications when there is a need to replace or supplement damaged or inadequate integumental tissue.
Brands: BIOVANCE® is a Decellularized, Dehydrated Human Amniotic Membrane allograft derived from the placenta. Interfyl® is a Human Connective Tissue Matrix derived from the chorionic plate of the placenta.